KarXT for schizophrenia-effectiveness and value: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
作者信息
McKenna Avery, Tice Jeffrey A, Whittington Melanie D, Wright Abigail C, Richardson Marina, Raymond Finn R, Pearson Steven D, Rind David M, Agboola Foluso
机构信息
Institute for Clinical and Economic Review, Boston, MA.
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco.
出版信息
J Manag Care Spec Pharm. 2024 Jun;30(6):624-628. doi: 10.18553/jmcp.2024.30.6.624.
Abstract
摘要
相似文献
1
KarXT for schizophrenia-effectiveness and value: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
J Manag Care Spec Pharm. 2024 Jun;30(6):624-628. doi: 10.18553/jmcp.2024.30.6.624.
2
The effectiveness and value of sotatercept for pulmonary arterial hypertension: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.
J Manag Care Spec Pharm. 2024 May;30(5):491-495. doi: 10.18553/jmcp.2024.30.5.491.
3
Xanomeline-Trospium in schizophrenia: A detailed review and comparison with the Institute for Clinical and Economic Review's analysis.
J Manag Care Spec Pharm. 2024 Jun;30(6):629-632. doi: 10.18553/jmcp.2024.30.6.629.
4
Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.
J Comp Eff Res. 2012 Mar;1(2):171-80. doi: 10.2217/cer.12.8.
5
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
Arch Gen Psychiatry. 2006 Oct;63(10):1069-72. doi: 10.1001/archpsyc.63.10.1069.
6
Impact of drug treatment history on comparative effectiveness research in schizophrenia.
Value Health. 2011 Jul-Aug;14(5):679-86. doi: 10.1016/j.jval.2011.02.002. Epub 2011 Jun 14.
7
Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
Pharmacoeconomics. 2015 Oct;33(10):1049-67. doi: 10.1007/s40273-015-0285-8.
8
Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?
Pharmacoeconomics. 2005;23 Suppl 1:1-2. doi: 10.2165/00019053-200523001-00001.
9
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
Health Technol Assess. 2010 Jan;14(3):1-157, iii. doi: 10.3310/hta14030.
10
Cost-effectiveness of schizophrenia pharmacotherapy.
Am J Psychiatry. 2007 Apr;164(4):678; author reply 678-9. doi: 10.1176/ajp.2007.164.4.678a.
引用本文的文献
1
New pharmacological approaches in the treatment of schizophrenia.
Pharmacol Rep. 2025 Jun;77(3):561-575. doi: 10.1007/s43440-025-00722-9. Epub 2025 Apr 8.
2
Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials.
BMC Psychiatry. 2025 Mar 31;25(1):309. doi: 10.1186/s12888-025-06696-5.
3
Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.
Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02077-4.
4
Schizophrenia and Bone Marrow Disorders: An Emerging Clinical Association.
Cureus. 2024 Dec 16;16(12):e75822. doi: 10.7759/cureus.75822. eCollection 2024 Dec.
5
Xanomeline/Trospium Chloride: First Approval.
Drugs. 2025 Jan;85(1):103-109. doi: 10.1007/s40265-024-02126-0. Epub 2024 Dec 24.
6
Revolutionary drug for schizophrenia wins US approval.
Nature. 2024 Oct;634(8033):276-277. doi: 10.1038/d41586-024-03123-9.
本文引用的文献
1
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14.
2
The Economic Burden of Schizophrenia in the United States.
J Clin Psychiatry. 2022 Oct 10;83(6):22m14458. doi: 10.4088/JCP.22m14458.
3
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
N Engl J Med. 2021 Feb 25;384(8):717-726. doi: 10.1056/NEJMoa2017015.
4
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.
Am J Psychiatry. 2020 Sep 1;177(9):868-872. doi: 10.1176/appi.ajp.2020.177901.
5
Schizophrenia.
N Engl J Med. 2019 Oct 31;381(18):1753-1761. doi: 10.1056/NEJMra1808803.
6
Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Value Health. 2014 Jun;17(4):310-9. doi: 10.1016/j.jval.2014.02.008. Epub 2014 May 10.
7
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Curr Med Res Opin. 2008 Nov;24(11):3275-85. doi: 10.1185/03007990802507547. Epub 2008 Oct 22.
8
A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.
Eur J Health Econ. 2006 Sep;7(3):165-72. doi: 10.1007/s10198-006-0347-0.
Zotero 插件